Literature DB >> 20336162

Cancer: antitumor effects of octreotide LAR, a somatostatin analog.

Kjell Oberg.   

Abstract

Treatment of nonfunctioning neuroendocrine tumors with somatostatin analogs has been controversial, given the low antitumor effects of these drugs. The ProMid study group now reports that octreotide lar (long-acting release) has a substantial antitumor effect, with longer progression-free survival compared with placebo in patients with well-differentiated neuroendocrine tumors and low tumor burden.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20336162     DOI： 10.1038/nrendo.2010.3

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  10 in total

Review 1.  Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.

Authors:  K Oberg; L Kvols; M Caplin; G Delle Fave; W de Herder; G Rindi; P Ruszniewski; E A Woltering; B Wiedenmann
Journal:  Ann Oncol       Date:  2004-06       Impact factor: 32.976

2.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; A Couvelard; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

3.  Complete histological regression of metastatic carcinoid tumour after treatment with octreotide.

Authors:  K E Imtiaz; P Monteith; A Khaleeli
Journal:  Clin Endocrinol (Oxf)       Date:  2000-12       Impact factor: 3.478

Review 4.  Rationale for the use of somatostatin analogs as antitumor agents.

Authors:  C Susini; L Buscail
Journal:  Ann Oncol       Date:  2006-06-26       Impact factor: 32.976

5.  Carcinoid tumors and syndrome.

Authors:  J M Feldman
Journal:  Semin Oncol       Date:  1987-09       Impact factor: 4.929

6.  Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands.

Authors:  J C Reubi; B Waser; J C Schaer; J A Laissue
Journal:  Eur J Nucl Med       Date:  2001-07

Review 7.  Neuroendocrine tumors. Biotherapy.

Authors:  U Plöckinger; B Wiedenmann
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2007-03       Impact factor: 4.690

Review 8.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

9.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

10.  Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report.

Authors:  Dan Granberg; Hans Jacobsson; Kjell Oberg; Jörgen Gustavsson; Mikael Lehtihet
Journal:  Digestion       Date:  2008-03-29       Impact factor: 3.216
  10 in total
  10 in total

1.  Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients.

Authors:  Beatrice Waser; Renzo Cescato; Qisheng Liu; Yachu J Kao; Meike Körner; Emanuel Christ; Agnes Schonbrunn; Jean Claude Reubi
Journal:  Am J Pathol       Date:  2012-05       Impact factor: 4.307

2.  Wilms tumor-suppressing peptide inhibits proliferation and induces apoptosis of Wilms tumor cells in vitro and in vivo.

Authors:  Wei Zhao; Juan Li; Ping Li; Fei Guo; Pengfei Gao; Junjie Zhang; Zechen Yan; Lei Wang; Da Zhang; Pan Qin; Guoqiang Zhao; Jiaxiang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-28       Impact factor: 4.553

Review 3.  Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch.

Authors:  Yvette Carter; Renata Jaskula-Sztul; Herbert Chen; Haggi Mazeh
Journal:  Neuroendocrinology       Date:  2012-02-14       Impact factor: 4.914

4.  [Immunohistochemical evaluation of somatostatin receptor subtypes in surgical pathology specimens of neuroendocrine tumors].

Authors:  H Sasano; S Iida; A Kasajima
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

5.  Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.

Authors:  Mohammad Abolhassani; Adeline Guais; Edward Sanders; Frédéric Campion; Iduna Fichtner; Jacques Bonte; Gianfranco Baronzio; Giammaria Fiorentini; Maurice Israël; Laurent Schwartz
Journal:  Invest New Drugs       Date:  2011-06-09       Impact factor: 3.850

Review 6.  Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs).

Authors:  Enrique Grande; Juan José Díez; Vanessa Pachón; Alfredo Carrato
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

7.  Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours.

Authors:  A Romer; D Seiler; N Marincek; P Brunner; M T Koller; Q K T Ng; H R Maecke; J Müller-Brand; C Rochlitz; M Briel; C Schindler; M A Walter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-02       Impact factor: 9.236

8.  Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin.

Authors:  Laurent Schwartz; Adeline Guais; Maurice Israël; Bernard Junod; Jean-Marc Steyaert; Elisabetta Crespi; Gianfranco Baronzio; Mohammad Abolhassani
Journal:  Invest New Drugs       Date:  2012-07-14       Impact factor: 3.850

9.  Metastatic Recurrence of Typical Pulmonary Carcinoid Accompanied by Carcinoid Syndrome, Successfully Treated with Octreotide LAR.

Authors:  Asako Yanagisawa; Satoshi Hirano; Shinichiro Shimizu; Takuma Hiroishi; Kohei Shikano; Noriko Hayama; Tetsuo Fujita; Hiroyuki Amano; Makoto Nakamura; Sukeyuki Nakamura; Hiroshi Tabeta
Journal:  Case Rep Oncol Med       Date:  2017-12-28

10.  Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study.

Authors:  Nicolas Marincek; Ann-Catherine Jörg; Philippe Brunner; Christian Schindler; Michael T Koller; Christoph Rochlitz; Jan Müller-Brand; Helmut R Maecke; Matthias Briel; Martin A Walter
Journal:  J Transl Med       Date:  2013-01-15       Impact factor: 5.531
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.